Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00414206
Other study ID # ATG003-201
Secondary ID
Status Terminated
Phase Phase 2
First received December 19, 2006
Last updated October 26, 2010
Start date March 2007
Est. completion date September 2009

Study information

Verified date October 2010
Source CoMentis
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUkraine: Ministry of Health
Study type Interventional

Clinical Trial Summary

This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration (NV-AMD).


Recruitment information / eligibility

Status Terminated
Enrollment 343
Est. completion date September 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Mecamylamine

Placebo


Locations

Country Name City State
Brazil Hospital de Olhos de Araraquara Araraquara
Brazil Centro Brasileiro de Ciências Visuais Belo Horizonte
Brazil Instituto da Visão Belo Horizonte
Brazil Centro Brasileiro de Cirurgia dos Olhos Goiânia
Brazil Hospital de Clinicas de Porto Alegre Porto Alegre
Brazil Hospital Universitário Clementino Fraga Filho Rio de Janeiro
Brazil Clínica de Olhos Dr. Suel Abujamra São Paulo
Brazil Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo São Paulo
Brazil Hospital de Olhos de São Paulo São Paulo
Brazil Hospital São Paulo - Setor de Pesquisa Clínica São Paulo
Czech Republic University Hospital Brno, Department of Ophthalmology Brno
Czech Republic Eye Clinic University Hospital Hradec Kralove
Czech Republic Ophthalmology Nemocnice Litomysl Litomyšl
Czech Republic University Hospital Olomouc, Department of Ophthalmology Olomouc
Czech Republic Faculty Hospital Kralovske Vinohrady, Dept. of Ophthalmology Prague
Czech Republic Cornea Lexum Praha Praha
Mexico Cif Biotec CP
Mexico Hospital Conde de Valenciana CP
Mexico Fundación Hospital "Nuestra Sra de la Luz" I.A.P. Delegación Cuauhtémoc
Mexico Asociación Para Evitar la Ceguera Mexico City
Mexico Hospital General de México Mexico City
Mexico Hospital San José Tec de Monterrey Monterrey
Poland Klinika Chorób Oczu Gdansk
Poland Oddzial Okulistyczny Okregowy Szpital Kolejowy Katowice
Poland Klinika Okulistyczna Lodz
Poland Oddzial Okulistyki, Samodzielny Publiczny Szpital Kliniczny Nr 1 Przemienienia Panskiego AM w Poznaniu Poznan
Poland Katedra i Klinika Okulistyki, Samodzielny Publiczny Kliniczny Szpital Okulistyczny Warsaw
Poland Katedra i Klinika Okulistyki, Akademia Medyczna we Wroclawiu Wroclaw
Russian Federation Republican Ophthalmologic Hospital of MH of Republic of Tatarstan Kazan
Russian Federation IRTC "Eye Microsurgery" n. a. S.N. Fyodorov Moscow
Russian Federation Moscow Scientific Research Institute of Eye Diseases Moscow
Russian Federation CJSC "Inter Yuna" Rostov-on Don
Russian Federation City Consultative Diagnostic Centre # 1 (St. Petersburg) St. Petersburg
Russian Federation IRTC "Eye Microsurgery" n. a. S.N. Fyodorov St. Petersburg
Russian Federation Military Medical Academy n.a. S.M.Kirov of Ministry of Defence St. Petersburg
Russian Federation St. Petersburg State Medical University n. a. Pavlov St. Petersburg
Ukraine Kyiv City Centre of Eye Vascular and Endocrine Diseases of Organ of Vision Kyiv
Ukraine Kyiv City Ophthalmologic Hospital Kyiv
Ukraine Kyiv City Ophthalmologic Hospital "Eye Microsurgery Centre" Kyiv
Ukraine V.P. Filatov Institute of Eye Diseases and Tissue Pathology of AMS of Ukraine Odessa
Ukraine Zaporizhzhya Center of Vision Rehabilitation Odessa
Ukraine S.I. Georgiyevsky Crimean State Medical University Simferopol

Sponsors (1)

Lead Sponsor Collaborator
CoMentis

Countries where clinical trial is conducted

Brazil,  Czech Republic,  Mexico,  Poland,  Russian Federation,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Subjects Losing Fewer Than 15 ETDRS Letters of Visual Acuity at 48 Weeks Compared to Baseline. Baseline to Week 48 No
See also
  Status Clinical Trial Phase
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed NCT02540954 - Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Phase 3
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Completed NCT02510794 - Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration Phase 2
Terminated NCT02228304 - Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Completed NCT02181504 - A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration Phase 2
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT01204541 - A Single-Center Pilot Study to Assess Macular Function N/A
Completed NCT00769392 - Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection N/A
Withdrawn NCT00538538 - Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) Phase 1
Completed NCT00533520 - Evaluation of Dosing Interval of Higher Doses of Ranibizumab Phase 4
Completed NCT00536016 - A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD Phase 1
Terminated NCT00403442 - Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD Phase 1
Recruiting NCT00157976 - Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Phase 3
Completed NCT00242580 - A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Phase 3
Completed NCT00211458 - Treatment of Age-Related Macular Degeneration With Anecortave Acetate Phase 2
Completed NCT00239928 - Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration Phase 2
Completed NCT00095433 - Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) Phase 3
Completed NCT00006202 - Lutein for Age-Related Macular Degeneration Phase 2

External Links